Posted inBiotechnology
Gilead, Arcus keep TIGIT dream alive with 27-month OS data from phase 2 cancer cohort
Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to 27 months,…